Skip to content

Clinical trials

Completed Urinary Bladder Neoplasms trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Urinary Bladder Neoplasms Status: Completed Country / region: United States Clear all

410 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200010
200112
20027
200310
200416
200513
200617
200718
200818
20098
20108
201112
201213
201316
201419
201522
201627
201722
201825
201920
202018
202115
202210
202310
20244
20252

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed410

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)30
Memorial Sloan Kettering Cancer Center28
M.D. Anderson Cancer Center15
UNC Lineberger Comprehensive Cancer Center10
Eastern Cooperative Oncology Group8
SWOG Cancer Research Network7
University of Kansas Medical Center7
Roswell Park Cancer Institute6
Bristol-Myers Squibb5
H. Lee Moffitt Cancer Center and Research Institute5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Urinary Bladder Neoplasms410
Carcinoma, Non-Small-Cell Lung73
Breast Neoplasms69
Prostatic Neoplasms68
Lung Neoplasms66
Pancreatic Neoplasms61
Ovarian Neoplasms57
Stomach Neoplasms54
Carcinoma, Renal Cell52
Uterine Cervical Neoplasms52

Trials

Showing 1 to 25 of 410. Each trial links to its page on Pharma Observatory.

310 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.